# Interface Biologics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/interface-biologics

- Industry: Biopolymers
- Headquarters: Toronto, Canada
- Website: www.interfacebiologics.com
- Total disclosed funding: $7M
- Latest round: Series B (Jan 13, 2015)
- Investors on record: 5

## About

Interface Biologics Inc specializes in innovative biomaterials and drug delivery solutions, enhancing patient outcomes through their advanced polymer-free technologies.Founded in 2001, Interface Biologics Inc is based in Toronto, Canada, and focuses on developing cutting-edge biomaterials and drug delivery systems. The company has successfully completed 8 deals, with its most recent funding round, a GROWTH round, occurring on January 13, 2015. This round raised CAD 1.000 mn from investors including BDC Capital. The company is led by CEO Tom Reeves, who has a background in biotechnology and has previously founded other ventures.Interface Biologics Inc develops advanced biomaterials that provide novel drug delivery solutions without the use of polymers. Their flagship technology, Epidel™, enables self-delivery of medications, improving treatment efficacy in conditions like retinal vein occlusion and diabetic macular edema. The company primarily serves ophthalmologists and healthcare institutions in North America and Europe, offering various implantable forms like cylinders and microspheres that release medications through controlled erosion.Interface Biologics Inc generates revenue through strategic partnerships and licensing agreements. Their recent collaboration with AbbVie includes upfront payments, milestone fees, and royalties on net sales for their implant RTC-620, targeting intraocular pressure reduction in glaucoma patients. Additionally, partnerships with companies like Glaukos Corporation support their revenue through potential licensing of innovative drug delivery technologies, ensuring continuous advancement in the ophthalmic therapeutics market.Looking ahead, Interface Biologics Inc plans to expand its product line, focusing on new drug delivery systems anticipated to launch by 2025. The company aims to enter additional markets in the Asia-Pacific and Latin America regions to meet the rising demand for innovative healthcare solutions. The funding raised in the latest GROWTH round will be allocated to research and development efforts, supporting the advancement of product offerings and market expansion initiatives.

## Funding rounds

- Series B, Jan 13, 2015 — BDC Capital, DSM Venturing, Koninklijke DSM N.V.
- Series B, Jan 10, 2011, $7M — VenGrowth Capital Partners, BDC Capital, Covington

## Investors

- VenGrowth Capital Partners (https://capitalatlas.ai/funds/vengrowth-capital-partners) — Series B
- BDC Capital (https://capitalatlas.ai/funds/bdc-capital) — Series B
- Covington (https://capitalatlas.ai/funds/covington) — Series B
- DSM Venturing (https://capitalatlas.ai/funds/dsm-venturing) — Series B
- Koninklijke DSM N.V. — Series B